Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Transcode Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial August 23, 2023 Designed to demonstrate delivery of TTX-MC138 to metastatic lesions"
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/28/2023 8-K Quarterly results
06/08/2023 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between TransCode Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purcha...",
"TransCode Therapeutics Announces Pricing of $7 Million Public Offering BOSTON, June 6, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its public offering of an aggregate of 2,000,000 shares of its common stock , together with accompanying common stock warrants, at a public offering price of $3.50 per share and accompanying warrants. Each share of common stock is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants will be exercisable immediately and will expire..."
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/18/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/14/2023 8-K Quarterly results
03/31/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
03/31/2023 8-K Quarterly results
Docs: "TransCode Therapeutics Reports 2022 Results; Provides Business Update"
02/01/2023 8-K Quarterly results
12/09/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/30/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
Docs: "TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update"
08/03/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology August 2, 2022 BOSTON and HOUSTON, Aug. 02, 2022 -- TransCode Therapeutics, Inc . , the RNA oncology company, and The University of Texas MD Anderson Cancer Cente r , today announced a strategic alliance to advance TransCode’ s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates. Through the alliance, TransCode and MD Anderson scientists will collaborate on preclinical studies to further validate TransCode’ s therapeutic and diagnostic candidates and to expand the reach of TransCode’ s discovery engine. The results of these studies will inform future clinical trials with these agents, including trials to be led at MD Anderson. “RNA-based therapeutics offer exciting p..."
06/23/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/01/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results"
09/30/2021 8-K Quarterly results
08/23/2021 8-K Quarterly results
07/13/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy